The model showed CD56+CTLA4+ > 33.29% for 100% of sarcoidosis patients, but CD56+CTLA4+ ≤ 33.29, CD4+PD1+ > 1.55% and CD8+ > 30.7% for 100% of GPA patients. This evidence concerns the gene CD8A and sarcoidosis.